AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15105678 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovered CBP (those with CBP in 1996 but not 2000)
Number of subjects: 2184
Study 15105678 — intervention group
Group type: COMPARATOR
Intervention: CBP prevalence in 1996
Number of subjects: 2184
Study 15105678 — intervention group
Group type: COMPARATOR
Intervention: CBP prevalence in 2000
Number of subjects: 2184
Study 11158692 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% cromolyn cream
Number of subjects: 26
Study 11158692 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 26
Study 9988054 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine up to 50 mg/day (n = 55)
Number of subjects: 128
Study 9988054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine up to 80 mg/day (n = 54)
Number of subjects: 128
Study 9988054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 128
Study 9988054 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine and Fluoxetine
Number of subjects: 128
Study 8306736 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory percussion (AusP)
Number of subjects: 63
Study 8306736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AusP and conventional auscultation (ConA)
Number of subjects: 63
Study 8306736 — intervention group
Group type: COMPARATOR
Intervention: Conventional percussion (ConP)
Number of subjects: 63
Study 8306736 — intervention group
Group type: COMPARATOR
Intervention: Conventional auscultation (ConA)
Number of subjects: 63
Study 2903059 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine 2 HCl
Number of subjects: 9
Study 2903059 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 9
Study 2903059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 4436447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cephradine (2 g) with probenecid (1 g)
Number of subjects: 0
Study 4436447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular cephradine (1 or 2 g) with probenecid (1 g)
Number of subjects: 0
Study 4436447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cephradine (500 mg) in fasting subjects
Number of subjects: 0
Study 4436447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cephradine (500 mg) in fed subjects
Number of subjects: 0
Study 31868134 — intervention group
Group type: EXPERIMENTAL
Intervention: Active talking role in conversation about heavy drinking
Number of subjects: 92
Study 31868134 — intervention group
Group type: COMPARATOR
Intervention: Passive listening role in conversation about heavy drinking
Number of subjects: 92
Study 31868134 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational effort
Number of subjects: 92
Study 31337174 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline infusion at 1 mL/second (slow speed, A group)
Number of subjects: 40
Study 31337174 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline infusion at 3 mL/second (rapid speed, B group)
Number of subjects: 40
Study 31337174 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups A and B
Number of subjects: 40
Study 28438144 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based HIV prevention intervention
Number of subjects: 800
Study 28438144 — intervention group
Group type: COMPARATOR
Intervention: Usual care (HIV/STDs knowledge brochure and free voluntary counseling services)
Number of subjects: 800
Study 24915562 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 125 mg every 12 hours during phototherapy
Number of subjects: 119
Study 24915562 — intervention group
Group type: COMPARATOR
Intervention: Placebo during phototherapy
Number of subjects: 119
Study 23793409 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 2
Study 23793409 — intervention group
Group type: COMPARATOR
Intervention: Interferon β 1a
Number of subjects: 2
Study 22336311 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose pituitrin (0.01 - 0.03 U/min) added to conventional treatment
Number of subjects: 48
Study 22336311 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (antibiotics, fluid resuscitation, glucocorticoids, organ support, dopamine 1-15 µg/(kg·min), norepinephrine 0.5-2 µg/(kg·min))
Number of subjects: 48
Study 18795367 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 13
Study 18795367 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 13
Study 16918520 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (0.016 mg/kg/IgE every 4 weeks)
Number of subjects: 19
Study 16918520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11135022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 26
Study 11135022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9023463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 900
Study 9023463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 9023463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation during summer
Number of subjects: 900
Study 9023463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 900
Study 8389181 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization (CE) with doxorubicin and Gelfoam with or without Lipiodol
Number of subjects: 232
Study 8389181 — intervention group
Group type: COMPARATOR
Intervention: Chemoembolization (CE) with doxorubicin and Gelfoam
Number of subjects: 232
Study 8389181 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization (CE) with cis-platinum, Lipiodol, and Gelfoam
Number of subjects: 232
Study 2446055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 13
Study 2446055 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 13
Study 29413063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led self-management intervention
Number of subjects: 10
Study 27886247 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AG, n=15)
Number of subjects: 45
Study 27886247 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion (MG, n=15)
Number of subjects: 45
Study 27886247 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, n=15)
Number of subjects: 45
Study 24107427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic belts
Number of subjects: 60
Study 24107427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 22100560 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperoxic challenge (P(ET)O(2) of 500 mm Hg with P(ET)CO(2) maintained at 38 mm Hg)
Number of subjects: 17
Study 22100560 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperoxic challenge
Number of subjects: 17
Study 19755414 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg for 4 days)
Number of subjects: 11
Study 19755414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 days)
Number of subjects: 11
Study 19162756 — intervention group
Group type: EXPERIMENTAL
Intervention: Isothermic hemodiafiltration
Number of subjects: 12
Study 19162756 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral hemodiafiltration
Number of subjects: 12
Study 16958712 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive therapeutic nurse-client relationships
Number of subjects: 28
Study 16958712 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal/social role preparation
Number of subjects: 28
Study 16958712 — intervention group
Group type: COMPARATOR
Intervention: Formal teaching
Number of subjects: 28
Study 16958712 — intervention group
Group type: COMPARATOR
Intervention: Instructions without nurse input
Number of subjects: 28
Study 14646761 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized Zr femoral component
Number of subjects: 0
Study 14646761 — intervention group
Group type: COMPARATOR
Intervention: CoCrMo femoral component
Number of subjects: 0
Study 12515132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (once, 48 hours before operation)
Number of subjects: 30
Study 12515132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (twice, 96 hours and 48 hours before operation)
Number of subjects: 30
Study 10832472 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg IVIG on the first day of life
Number of subjects: 76
Study 10832472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVIG)
Number of subjects: 76
Study 8180536 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management for 56 patients admitted to three hospitals
Number of subjects: 126
Study 8180536 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation services
Number of subjects: 126
Study 3371858 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (6.0 mg for the first 5 days, 4.5 mg for the following week, and then 3.0 mg)
Number of subjects: 38
Study 3371858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29499504 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered DBT skills training (iDBT-ST)
Number of subjects: 59
Study 29499504 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 59
Study 27039954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 15
Study 27039954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 27039954 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (opioid blocker)
Number of subjects: 15
Study 26349124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Pulsar manual brush (OBP)
Number of subjects: 0
Study 26349124 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Whitening manual brush (CW)
Number of subjects: 0
Study 23590986 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy and 3 courses of FOLFOX4 (schedule I)
Number of subjects: 97
Study 23590986 — intervention group
Group type: COMPARATOR
Intervention: 50.4 Gy delivered in 28 fractions with 5‐Fu, leucovorin and oxaliplatin (schedule II)
Number of subjects: 97
Study 21664512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg daily for three cycles
Number of subjects: 10
Study 21664512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg every other day for three cycles
Number of subjects: 10
Study 21664512 — intervention group
Group type: COMPARATOR
Intervention: Control cycles (not explicitly defined in the abstract)
Number of subjects: 10
Study 18294410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 100 mg
Number of subjects: 61
Study 18294410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal tramadol 100 mg
Number of subjects: 61
Study 18294410 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 61
Study 16216400 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild positive affect
Number of subjects: 0
Study 16216400 — intervention group
Group type: COMPARATOR
Intervention: Negative affect
Number of subjects: 0
Study 16216400 — intervention group
Group type: COMPARATOR
Intervention: Neutral affect
Number of subjects: 0
Study 12700448 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 298
Study 12700448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 298
Study 12700448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 298
Study 11121720 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper supplementation (3 or 6 mg/d)
Number of subjects: 0
Study 11121720 — intervention group
Group type: COMPARATOR
Intervention: Control diets (0.7/1.6/6.0 mg/d)
Number of subjects: 0
Study 8594164 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term drug abuse treatment (23-day duration)
Number of subjects: 0
Study 1695312 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (7.5 mg b.i.d.)
Number of subjects: 17
Study 293493 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing therapy for a total of six years
Number of subjects: 83
Study 293493 — intervention group
Group type: COMPARATOR
Intervention: Stopping therapy after three years
Number of subjects: 83
Study 31349945 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10
Number of subjects: 86
Study 31349945 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 86
Study 31349945 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 plus Vitamin E
Number of subjects: 86
Study 31349945 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 and Vitamin E (alone or in combination)
Number of subjects: 86
Study 28181728 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 16492
Study 28181728 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16492
Study 25458262 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplant (34 patients)
Number of subjects: 65
Study 25458262 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplant (31 patients)
Number of subjects: 65
Study 24246597 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) for 2 hours daily between days of life 5 to 10
Number of subjects: 38
Study 24246597 — intervention group
Group type: COMPARATOR
Intervention: Standard incubator care
Number of subjects: 38
Study 20955771 — intervention group
Group type: EXPERIMENTAL
Intervention: Rauvolfia-Citrus tea
Number of subjects: 23
Study 20955771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 19349317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous reconstituted HDL (rHDL: 80 mg/kg over 4 hours)
Number of subjects: 13
Study 19349317 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL and apolipoprotein AI
Number of subjects: 13
Study 16426899 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0
Study 16426899 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 0
Study 16426899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 14988449 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein depleted of isoflavones
Number of subjects: 36
Study 14988449 — intervention group
Group type: COMPARATOR
Intervention: Animal protein with no added isoflavones
Number of subjects: 36
Study 14988449 — intervention group
Group type: COMPARATOR
Intervention: Animal protein with added isoflavones
Number of subjects: 36
Study 11706339 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiographs of the fractured and normal wrists
Number of subjects: 38
Study 11706339 — intervention group
Group type: COMPARATOR
Intervention: Standard radiographs of the uninjured wrist
Number of subjects: 38
Study 9322632 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (25 microgram tablets every 4 hours for a maximum of six doses)
Number of subjects: 200
Study 9322632 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (10 mg vaginal insert for a maximum of 24 hours)
Number of subjects: 200
Study 7993573 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose OKT3 (5 mg)
Number of subjects: 26
Study 7993573 — intervention group
Group type: COMPARATOR
Intervention: Low-dose OKT3 (2 mg)
Number of subjects: 26
Study 3054035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid (55 mg/kg/day for 5 days)
Number of subjects: 68
Study 3054035 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (100 mg/kg/day for 5 days)
Number of subjects: 68
Study 3054035 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-resistant group (ampicillin-R)
Number of subjects: 68
Study 3054035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid
Number of subjects: 68
Study 3054035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid and Ampicillin
Number of subjects: 68
Study 30877049 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 64
Study 30877049 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 64
Study 31216900 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT intervention (details not specified)
Number of subjects: 2
Study 28096757 — intervention group
Group type: EXPERIMENTAL
Intervention: PWS (pre-workout dietary supplement)
Number of subjects: 80
Study 28096757 — intervention group
Group type: EXPERIMENTAL
Intervention: PWS + S (pre-workout dietary supplement with synephrine)
Number of subjects: 80
Study 28096757 — intervention group
Group type: COMPARATOR
Intervention: PLA (flavored placebo)
Number of subjects: 80
Study 28096757 — intervention group
Group type: EXPERIMENTAL
Intervention: PWS and PWS + S
Number of subjects: 80
Study 25925713 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601 (NeuroAiD)
Number of subjects: 880
Study 25925713 — intervention group
Group type: COMPARATOR
Intervention: Standard care and rehabilitation
Number of subjects: 880
Study 22476876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavonoid diet (HF)
Number of subjects: 174
Study 22476876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flavonoid diet (LF)
Number of subjects: 174
Study 22476876 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 174
Study 21676480 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c of 5.7%
Number of subjects: 9723
Study 21676480 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c range of 5.7-6.4%
Number of subjects: 9723
Study 19935022 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with combined ketorolac and lidocaine
Number of subjects: 50
Study 19935022 — intervention group
Group type: COMPARATOR
Intervention: Paracervical block with lidocaine alone
Number of subjects: 50
Study 16797309 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil treatment
Number of subjects: 39
Study 16797309 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 39
Study 16797309 — intervention group
Group type: COMPARATOR
Intervention: Control group without ED
Number of subjects: 39
Study 12587810 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist comanagement (PPCM)
Number of subjects: 197
Study 12587810 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 197
Study 11023085 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA 150 g daily
Number of subjects: 29
Study 11023085 — intervention group
Group type: COMPARATOR
Intervention: Standardized diet with 80 g protein daily
Number of subjects: 29
Study 9407258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-oryzanol supplementation (500 mg.day-1)
Number of subjects: 50
Study 9407258 — intervention group
Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 50
Study 1316722 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatwell work-site nutrition intervention program (direct education and environmental programming)
Number of subjects: 16
Study 1316722 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study 3918190 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral penicillin for 72 hours
Number of subjects: 44
Study 3918190 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 72 hours
Number of subjects: 44
Study 30252895 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial pulsed electromagnetic field treatment (squared bipolar 3 ms pulses, 50 Hz) for 30 min/day for 8 weeks
Number of subjects: 97
Study 30252895 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 30 min/day for 8 weeks
Number of subjects: 97
Study 27209465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid
Number of subjects: 162
Study 27209465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 900 μg sc bid
Number of subjects: 162
Study 25414932 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/d
Number of subjects: 1961
Study 25414932 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin + insulin +/‐ metformin
Number of subjects: 1961
Study 25414932 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 1961
Study 25414932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1961
Study 21675122 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells transplantation
Number of subjects: 27
Study 21675122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cells transplantation)
Number of subjects: 27
Study 19218179 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 851
Study 19218179 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 851
Study 17978322 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG intervention
Number of subjects: 507
Study 17978322 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 507
Study 15130080 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Balance gel (used three times a day for 90 days)
Number of subjects: 21
Study 15130080 — intervention group
Group type: COMPARATOR
Intervention: gel placebo (used three times a day for 90 days)
Number of subjects: 21
Study 11328911 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 135
Study 11328911 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 135
Study 9164361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms once daily for 4 weeks
Number of subjects: 106
Study 9164361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 8431629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly pain assessments for 48 hours using VAS
Number of subjects: 84
Study 8431629 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour recall of worst pain
Number of subjects: 84
Study 2959626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitissue immunoglobulins (Sérocytol Neuro‐Vasculaire) administered by intradermal injections
Number of subjects: 44